Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732657 | 0.85 | L3MBTL1 (0.69) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL4022892 | 0.85 | L3MBTL1 (0.62) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL30636822 | 0.84 | L3MBTL1 (0.49) | L3MBTL1ACHE | |
| SCHEMBL18038382 | 0.83 | L3MBTL1 (0.71) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL4240582 | 0.81 | L3MBTL1 (1.00) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL27716505 | 0.81 | L3MBTL1 (0.69) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL30173684 | 0.81 | L3MBTL1 (0.63) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL31681673 | 0.80 | L3MBTL1 (0.67) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL30535495 | 0.80 | L3MBTL1 (0.67) | L3MBTL1ALKBH2HPGDSACHECYP4F2 | |
| SCHEMBL24828550 | 0.80 | L3MBTL1 (0.49) | L3MBTL1ACHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA2 | L3MBTL1 3420/4885ALKBH2 4177/4885HPGDS 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.